- Report
- March 2024
- 148 Pages
Global
From €3764EUR$3,899USD£3,188GBP
- Report
- March 2024
- 145 Pages
Global
From €3764EUR$3,899USD£3,188GBP
- Report
- November 2023
- 144 Pages
Global
From €2413EUR$2,499USD£2,043GBP
- Report
- February 2024
- 175 Pages
Global
From €4828EUR$5,000USD£4,088GBP
- Report
- January 2024
- 200 Pages
Global
From €4828EUR$5,000USD£4,088GBP
- Report
- January 2024
- 200 Pages
Global
From €4828EUR$5,000USD£4,088GBP
- Report
- January 2024
- 200 Pages
Global
From €4828EUR$5,000USD£4,088GBP
- Report
- May 2024
- 182 Pages
Global
From €4731EUR$4,900USD£4,006GBP
- Report
- April 2024
- 185 Pages
Global
From €4731EUR$4,900USD£4,006GBP
- Report
- November 2023
- 179 Pages
Global
From €4731EUR$4,900USD£4,006GBP
- Report
- November 2023
- 182 Pages
Global
From €4731EUR$4,900USD£4,006GBP
- Report
- May 2024
- 180 Pages
Global
From €4731EUR$4,900USD£4,006GBP
- Report
- April 2024
- 185 Pages
Global
From €4731EUR$4,900USD£4,006GBP
- Report
- April 2024
- 180 Pages
Global
From €4731EUR$4,900USD£4,006GBP
- Report
- October 2023
- 182 Pages
Global
From €4731EUR$4,900USD£4,006GBP
- Report
- October 2023
- 180 Pages
Global
From €4731EUR$4,900USD£4,006GBP
- Report
- July 2023
- 145 Pages
Global
From €4779EUR$4,950USD£4,047GBP
- Report
- February 2024
- 115 Pages
Global
From €4586EUR$4,750USD£3,883GBP
- Report
- February 2024
- 111 Pages
Global
From €4586EUR$4,750USD£3,883GBP
- Report
- February 2024
- 115 Pages
Global
From €4586EUR$4,750USD£3,883GBP
The Liquid Biopsy market within the Pharmaceuticals industry is a rapidly growing field of research and development. It is a minimally invasive procedure that uses a sample of blood to detect and monitor cancer. It is used to detect cancer at an early stage, to monitor the progression of the disease, and to assess the effectiveness of treatments. Liquid biopsy can also be used to detect genetic mutations associated with cancer, which can help guide treatment decisions.
The Liquid Biopsy market is expected to grow significantly in the coming years due to its potential to improve patient outcomes and reduce healthcare costs. It is also expected to benefit from advances in technology, such as the development of more sensitive and specific tests.
Some companies in the Liquid Biopsy market include Guardant Health, Exact Sciences, Biocept, and Genomic Health. Show Less Read more